A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
EvolveImmune United, Inc
Seagen Inc.
Pfizer
IDEAYA Biosciences
Rondo Therapeutics
Neonc Technologies, Inc.
Novartis
MacroGenics
Innate Pharma
NeoTX Therapeutics Ltd.
DualityBio Inc.
Incyte Corporation
Incyte Corporation
Cofactor Genomics, Inc.
Seagen Inc.
Molecular Templates, Inc.
Keythera (Suzhou) Pharmaceuticals Co. Ltd
Atreca, Inc.
Gossamer Bio Inc.